The Technical AnalystExchange: OSE Industry: Pharmaceuticals, Biotechnology & Life Sciences
BerGenBio ASA Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.21% NOK0.147
Europe/Oslo / 30 apr 2024 @ 12:28
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 580.75 mill |
| EPS: | -0.550 |
| P/E: | -0.270 |
| Earnings Date: | May 29, 2024 |
| SharesOutstanding: | 3 956.06 mill |
| Avg Daily Volume: | 42.95 mill |
| RATING 2024-04-30 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.270 | sector: PE 22.86 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.270 | industry: PE 33.94 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
NOK0.189 (29.04%) NOK0.0426 |
| Date: 2024-04-30 |
| Expected Trading Range (DAY) |
|---|
|
NOK 0.128 - 0.164 ( +/- 12.30%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
-10.00
Sell
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | NOK0.147 (-1.21% ) |
| Volume | 13.58 mill |
| Avg. Vol. | 42.95 mill |
| % of Avg. Vol | 31.61 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BGBIO.OL
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:40 | sell | NOK0.306 | N/A | Active |
|---|
BGBIO.OL
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.